Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands.
Saved in:
| Title: | Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands. |
|---|---|
| Authors: | Pennings ERA; Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands. e.r.a.pennings@amsterdamumc.nl.; Cancer Center Amsterdam, Amsterdam, The Netherlands. e.r.a.pennings@amsterdamumc.nl.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands. e.r.a.pennings@amsterdamumc.nl.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. e.r.a.pennings@amsterdamumc.nl., Durmaz M; Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands., Visser O; Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands., Posthuma EFM; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Internal Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands., Issa DE; Department of Internal Medicine, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Chamuleau MED; Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Lugtenburg PJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands., Kersten MJ; Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands., Dinmohamed AG; Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands. a.dinmohamed@iknl.nl.; Cancer Center Amsterdam, Amsterdam, The Netherlands. a.dinmohamed@iknl.nl.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands. a.dinmohamed@iknl.nl.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. a.dinmohamed@iknl.nl.; Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. a.dinmohamed@iknl.nl.; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. a.dinmohamed@iknl.nl. |
| Source: | Blood cancer journal [Blood Cancer J] 2024 Jan 04; Vol. 14 (1), pp. 3. Date of Electronic Publication: 2024 Jan 04. |
| Publication Type: | Letter; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-023-00970-z |
